Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers

Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, has expanded its product portfolio with the introduction of a disposable pen injector. Ideally suited for high-volume manufacturing, Phillips-Medisize offers pharmaceutical companies a familiar highly competitive pen injector to facilitate faster, more efficient and cost-effective market entry.

Latest Aithority Insights : Canvas GFX Launches New Consumer and Single-User Graphics and Sharing Solution, Envision .evONE

“A Pen Injector is an important addition to Phillips-Medisize’s expanding product and platform portfolio that empowers Biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale,” said Paul Chaffin, senior vice president and president of Medical and Pharmaceutical Solutions, Molex. “This ‘ready to go’ solution offers all of the advantages expected from ‘state of the art’ pen designs, while benefiting from our decades of device development and large-volume manufacturing expertise to reduce the challenges of bringing affordable drugs and drug-delivery devices to market.”

Browse The Complete News About Aithority: Hg joins EQT and TA Associates as investors in IFS and WorkWave

Related Posts
1 of 35,098
Flexible Design, Smaller Form Factor and Reduced Costs

The pen injector has been designed to match user expectations and experiences with familiar disposable pen products, yet is noticeably smaller than most comparable offerings in the market. In addition to its compact form factor, this pen injector features a flexible design with customizable dosing as well as push-button colors to signal different dosing and drug requirements for multiple therapies, including diabetes, fertility, growth hormones, obesity and osteoporosis.

Sample devices are available to support technical evaluation and human factors studies, with clinical devices scheduled for the end of 2023. As a result, this pen injector is strongly positioned to help drug-delivery companies respond to the rapidly rising, billion-unit-plus disposable pen injector market while reducing commercialization costs and risks.

Read More About Aithority News : Opera Takes a Giant Leap Into Web3, Integrates Solana, Polygon, StarkEx, and Others

 [To share your insights with us, please write to]

Comments are closed.